Do beta-blockers worsen respiratory status for patients with COPD?

Lynda M. Baselli, MD; Mark A. Oswald, MD
West Jersey–Memorial Family Practice Residency at Virtua, Voorhees, NJ
Joan M. Nashelsky, MLS
Family Physicians Inquiries Network, Inc, Iowa City

EVIDENCE-BASED ANSWER

Patients with chronic obstructive pulmonary disease (COPD) who use cardioselective beta-blockers (beta1-blockers) do not experience a significant worsening of their short-term pulmonary status as measured by changes in forced expiratory volume in 1 second (FEV1), or by changes in patients’ self-reported symptoms. If such harmful effects do exist, they are likely to be less clinically important than the substantial proven benefits of beta-blockade for patients with concomitant cardiovascular disease (strength of recommendation: A, based on a high-quality meta-analysis of controlled trials).

Limited evidence suggests that most patients with congestive heart failure and COPD without reversible airflow obstruction tolerate carvedilol, which causes both nonselective beta- and alpha-adrenergic blockade (SOR: B, based on limited-quality cohort studies).

CLINICAL COMMENTARY

Benefits outweigh risks for beta-blockade for patients with CV disease, comorbid COPD

It appears that the benefits outweigh the risks for the use of cardioselective beta-blocker therapy in patients with cardiovascular disease and comorbid COPD. Prudent management of these patients dictates that beta-blocker therapy should be initiated with a low-dose cardioselective beta-blocker, that the respiratory status of these patients should be monitored closely, and that any otherwise unexplained decline in respiratory status should warrant a reevaluation of the appropriateness of beta-blocker therapy.

Evidence summary

In recent years, beta-blockers have been shown to substantially decrease mortality in patients with congestive heart failure, coronary heart disease, and hypertension. Patients with both cardiovascular disease and COPD, however, are much less likely to receive beta-blocker therapy than comparable patients without COPD. Clinicians may be fearful of using beta-blockers in these patients because of the possibility of worsening respiratory function from the potential side effect of bronchoconstriction.1

A 2004 meta-analysis synthesized the data of 19 clinical controlled trials that compared active therapy with either placebo or prior-to-treatment controls, assessing differences in FEV1, response to a beta2-agonist, and patient-reported respiratory symptoms.2 Trials included in the meta-analysis used cardioselective beta-blockers and evaluated either single-dose treatments or therapy of longer duration.
(2 days to 3.3 months). The authors concluded that patients with COPD who received cardioselective beta-blockers (such as metoprolol, atenolol, or bisoprolol) did not experience a statistically significant short-term deterioration in FEV₁, worsening of COPD symptoms, or decreased responsiveness to beta₂-agonists. The authors reported similar results for an analysis restricted to only those patients with severe COPD.

This meta-analysis was limited by the relatively small number of participants (N=141 in single-dose treatment studies; N=126 in studies of longer duration treatment) in the handful of eligible studies. Consequently, rare or minimally harmful effects could have gone undetected.

A retrospective analysis of a cohort study analyzed the tolerability of carvedilol, a nonselective beta- and alpha-adrenergic blocker, in patients with COPD who had been taking the medication for at least 3 months. Eighty-five percent of the 89 patients with COPD tolerated carvedilol. The authors of the study (which was funded by the manufacturer of carvedilol) did not state why the other 15% of patients did not tolerate carvedilol, nor did they mention whether the patients with COPD had reversible airflow obstruction.

One of the sites that participated in this study subsequently published a smaller retrospective analysis of a cohort study that examined the outcomes of 31 patients with heart failure and COPD without reversible airflow obstruction who were started on carvedilol therapy. Over the 2.4 years that the patients were followed, 1 patient stopped taking carvedilol (mean dose 29 ± 19 mg daily) due to wheezing. Whether these 31 patients were also included in the larger study is unclear.

A 2004 narrative review article cited these 2 studies and concluded that carvedilol was well-tolerated in patients with COPD without reversible airflow obstruction, but no evidence exists regarding its tolerability in patients with reversible airflow obstruction.

**Recommendations from others**

A 2002 evidence-based clinical guideline on the diagnosis and management of COPD reported that the use of cardioselective beta-blockers in patients with COPD did not significantly worsen respiratory status, citing a previous version of the meta-analysis reviewed above as its source of evidence. The American College of Cardiology and the American Heart Association recommended the cautious administration of low-dose, short-acting cardioselective beta-blockers for acute coronary syndrome in patients with COPD.

A recent consensus workshop summary report issued by experts convened by the National Heart, Lung, and Blood Institute, cited continuing uncertainty regarding the use of beta-blockers for COPD patients with heart disease, and called for additional studies of management strategies for these often-coexisting conditions.

**References**